Manfred Wirth, Peter Iversen, David McLeod, William See

Slides:

Advertisements

Similar presentations

Medical Management for BPH: The Role of Combination Therapy

Advertisements

European Journal of Cancer

The PSA Era is not Over for Prostate Cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management Michael O’Leary European Urology Supplements

Volume 47, Issue 4, Pages (April 2005)

Volume 53, Issue 4, Pages (April 2008)

Volume 52, Issue 5, Pages (November 2007)

Prostate Cancer 2008: Challenges in Diagnosis and Management

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

Volume 51, Issue 4, Pages (April 2007)

Volume 70, Issue 4, Pages (October 2016)

Volume 53, Issue 5, Pages (May 2008)

Volume 71, Issue 5, Pages (May 2017)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

What is New in Hormone Therapy for Prostate Cancer in 2007?

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Localised and Locally Advanced Prostate Cancer: Who to Treat and How?

Counselling the Prostate Cancer Patient

Laurent Boccon-Gibod European Urology Supplements

Prostate Cancer Epidemic in Sight?

Advances in the Therapy of Prostate Cancer–Induced Bone Disease: Current Insights and Future Perspectives on the RANK/RANKL Pathways Kurt Miller, Arnulf.

The PSA Era is not Over for Prostate Cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer Matthew R. Smith European Urology Supplements

Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care Fred Saad, Carl Olsson, Claude C. Schulman

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 48, Issue 6, Pages (December 2005)

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Prostate Specific Antigen Doubling Time as Auxiliary End Point in Hormone Refractory Prostatic Carcinoma Hans-Peter Schmid, Rudolf Morant, Jürg Bernhard,

Volume 55, Issue 6, Pages (June 2009)

What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006 Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,

Testicular Cancer Variations in Time and Space in Europe

Jacques Irani European Urology Supplements

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Neal Shore European Urology Supplements

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Hormonal Therapy: Who Would Benefit?

The Hallmarks of BPH Progression and Risk Factors

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Christian Stief European Urology Supplements

Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma Fred Saad European Urology.

New Trends in Managing the Prostate Cancer Patient

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Prostate Cancer 2008: Challenges in Diagnosis and Management

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Richard Berges European Urology Supplements

Improving Flexibility and Quality of Life for Your Patients: A Must?

Highlighting Unmet Needs: Real Patients, Difficult Choices

The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients Kurt Miller European Urology Supplements Volume.

Management of Prostate Cancer: Global Strategies

Beyond Skeletal-Related Events

Treatment Options in Prostate Cancer Once Primary Therapy Fails

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Joaquim Bellmunt European Urology Supplements

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Epidemiology and Demographics of Prostatitis

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Guru Sonpavde, MD, Teresa G. Hayes, MD Mayo Clinic Proceedings

Does PSA Testing Influence the Natural History of Prostate Cancer?

Volume 51, Issue 5, Pages (May 2007)

Michael Marberger European Urology Supplements

Introduction European Urology Supplements

Presentation transcript:

Immediate Therapy in Early Prostate Cancer: Results from the Bicalutamide (‘Casodex’) EPC Programme Manfred Wirth, Peter Iversen, David McLeod, William See European Urology Supplements Volume 1, Issue 7, Pages 20-25 (October 2002) DOI: 10.1016/S1569-9056(02)00083-0

Fig. 1 (a) Kaplan–Meier curve of time to objective progression showing an increase in time to progression with bicalutamide 150mg treatment plus standard care compared with placebo plus standard care. (b) Incidence of objective progression events. European Urology Supplements 2002 1, 20-25DOI: (10.1016/S1569-9056(02)00083-0)

Fig. 2 Incidence of bone metastases or death within 2 years of randomisation. European Urology Supplements 2002 1, 20-25DOI: (10.1016/S1569-9056(02)00083-0)

Fig. 3 Kaplan–Meier curve of time to PSA doubling. European Urology Supplements 2002 1, 20-25DOI: (10.1016/S1569-9056(02)00083-0)